| Literature DB >> 27467165 |
Liangsheng Guo1, Xueguan Lu2,3, Lijun Zheng4, Xianying Liu5, Min Hu1.
Abstract
Long non-coding RNAs (lncRNAs), HOTAIR has been reported to be upregulated in cervical cancer development and progression. However, SNPs (single nucleotide polymorphisms) in the lncRNAs and their associations with cervical cancer susceptibility have not been reported. In the current study, we hypothesized that SNPs within the lncRNA HOTAIR may influence the risk of cervical cancer. We performed a case-control study including 510 cervical cancer patients (cases) and 713 cancer-free individuals (controls) to investigate the association between three haplotype-tagging SNPs (rs920778, rs1899663 and rs4759314) in the lncRNA HOTAIR and the risk of cervical cancer. We found a strong association between the SNP rs920778 in the intronic enhancer of the HOTAIR and cervical cancer (P<10-4). Moreover, the cervical cancer patients with homozygous TT genotype were significantly associated with tumor-node-metastasis (TNM) stage. In vitro assays with allele-specific reporter constructs indicated that the reporter constructs bearing rs920778T allele conferred elevated reporter gene transcriptional activity when compared to the reporter constructs containing rs920778C allele. Furthermore, HOTAIR expression was higher in cervical cancer tissues than that in corresponding normal tissues, and the high expression was associated with the risk-associated allele T. In summary, our studies provide strong functional evidence that functional SNP rs920778 regulates HOTAIR expression, and may ultimately influence the predisposition for cervical cancer.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27467165 PMCID: PMC4965140 DOI: 10.1371/journal.pone.0160039
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic characteristic of patients with cervical cancer and controls.
| Patients | Controls | |||
|---|---|---|---|---|
| Clinical parameters | N. | (%) | N. | (%) |
| 43±7.3 | 44±9.1 | |||
| ≤45 | 263 | (51.6) | 344 | (48.2) |
| >45 | 247 | (48.4) | 369 | (51.8) |
| Yes | 75 | (14.7) | 94 | (13.2) |
| No | 435 | (85.3) | 619 | (86.8) |
| Yes | 31 | (6.1) | 39 | (5.5) |
| No | 479 | (93.9) | 674 | (94.5) |
| Yes | 37 | (7.3) | 62 | (8.7) |
| No | 473 | (92.7) | 651 | (91.3) |
| Adenocarcinoma | 25 | (4.9) | ||
| Squamous cell | 394 | (77.3) | ||
| others | 91 | (17.8) | ||
| 0 | 71 | (13.9) | ||
| I | 177 | (34.8) | ||
| II | 193 | (37.9) | ||
| III | 67 | (13.1) | ||
| IV | 2 | (0.3) | ||
| High-moderate | 375 | (73.6) | ||
| low | 78 | (15.3) | ||
| unknown | 57 | (11.1) | ||
| Yes | 423 | (82.9) | ||
| No | 87 | (17.1) | ||
*Family history of cancer represents as a history of all human cancers in the parents, brothers and sisters.
Distribution of allele/genotype frequency of three haplotype-tagging SNPs in HOTAIR and their association with cervical cancer risk.
| Cases | Controls | |||||
|---|---|---|---|---|---|---|
| Polymorphisms | N = 510 | (%) | N = 713 | (%) | Adjusted OR | |
| CC | 269 | (52.75) | 448 | (62.83) | 1.00 (Reference) | |
| CT | 189 | (37.06) | 235 | (32.96) | 1.34 (1.05–1.76) | |
| TT | 52 | (10.20) | 30 | (4.21) | 2.88 (1.76–4.71) | |
| CT+TT | 241 | (47.25) | 265 | (37.17) | 1.51 (1.21–1.91) | |
| Allele | ||||||
| C | 727 | (71.27) | 1131 | (79.31) | 1.00 (Reference) | |
| T | 293 | (28.73) | 295 | (20.69) | 1.58 (1.31–1.89) | |
| GG | 356 | (69.80) | 509 | (71.39) | 1.00 (Reference) | |
| GT | 146 | (28.63) | 191 | (26.79) | 1.07 (0.88–1.45) | 0.645 |
| TT | 8 | (1.57) | 13 | (1.82) | 0.88 (0.35–2.29) | |
| GT+TT | 154 | (30.20) | 204 | (28.61) | 1.09 (0.86–1.37) | |
| Allele | ||||||
| G | 858 | (84.12) | 1209 | (84.78) | 1.00 (Reference) | |
| T | 162 | (15.88) | 217 | (15.22) | 1.06 (0.84–1.37) | 0.654 |
| AA | 378 | (74.12) | 544 | (76.30) | 1.00 (Reference) | |
| AG | 121 | (23.73) | 158 | (22.16) | 1.06 (0.87–1.49) | 0.316 |
| GG | 11 | (2.16) | 11 | (1.54) | 1.41 (0.59–3.58) | |
| AG+GG | 132 | (25.88) | 169 | (23.70) | 1.15 (0.91–1.42) | |
| Allele | ||||||
| A | 877 | (85.98) | 1246 | (87.38) | 1.00 (Reference) | |
| G | 143 | (14.02) | 180 | (12.62) | 1.17 (0.93–1.41) | 0.314 |
Abbreviations: OR, odds ratio; CI, confidence interval; N, number
aData were calculated by logistic regression analysis adjusted for age, smoking status, drinking status and family history of cancer.
bPvalue for Chi-square analysis.
Stratified analyses of lncRNA HOTAIR polymorphisms with clinical characteristics of patients with cervical cancer.
| Variables | Cases (N = 510) | Controls (N = 713) | Adjusted OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CC | (%) | CT/TT | (%) | CC | (%) | CT/TT | (%) | CT/TT | ||
| ≤45 | 65 | (12.75) | 198 | (38.82) | 114 | (15.99) | 230 | (32.26) | 1.51 (1.05–2.61) | 0.35 |
| >45 | 204 | (40.00) | 43 | (8.43) | 334 | (46.84) | 35 | (4.91) | 2.01 (1.25–3.25) | |
| Yes | 43 | (8.43) | 32 | (6.27) | 57 | (7.99) | 37 | (5.19) | 1.15 (0.62–2.12) | 0.34 |
| No | 226 | (44.31) | 209 | (40.98) | 391 | (54.84) | 228 | (31.98) | 1.59 (1.24–2.03) | |
| Yes | 21 | (4.12) | 10 | (1.96) | 29 | (4.07) | 10 | (1.40) | 1.38 (0.49–3.93) | 0.85 |
| No | 248 | (48.63) | 231 | (45.29) | 419 | (58.77) | 255 | (35.76) | 1.52 (1.28–1.91) | |
| Yes | 17 | (3.33) | 20 | (3.92) | 26 | (3.65) | 36 | (5.05) | 0.86 (0.35–1.88) | 0.14 |
| No | 252 | (49.41) | 221 | (43.33) | 422 | (59.19) | 229 | (32.12) | 1.66 (1.21–2.04) | |
| Adenocarcinoma | 11 | (2.16) | 14 | (2.75) | 448 | (62.83) | 265 | (37.17) | 2.16 (1.01–4.82) | |
| Squamous cell | 210 | (41.18) | 184 | (36.08) | 448 | (62.83) | 265 | (37.17) | 1.46 (1.13–1.85) | 0.68 |
| others | 48 | (9.41) | 43 | (8.43) | 448 | (62.83) | 265 | (37.17) | 1.55 (1.02–2.34) | |
| 0+I | 154 | (30.20) | 94 | (18.43) | 448 | (62.83) | 265 | (37.17) | 1.02 (0.79–1.36) | |
| II+III+IV | 115 | (22.55) | 147 | (28.82) | 448 | (62.83) | 265 | (37.17) | 2.17 (1.58–2.89) | |
| High-moderate | 194 | (38.04) | 181 | (35.49) | 448 | (62.83) | 265 | (37.17) | 1.57 (1.19–2.07) | |
| low | 43 | (8.43) | 35 | (6.86) | 448 | (62.83) | 265 | (37.17) | 1.39 (0.88–2.25) | 0.78 |
| unknown | 32 | (6.27) | 25 | (4.90) | 448 | (62.83) | 265 | (37.17) | 1.31 (0.73–2.31) | |
| Yes | 219 | (42.94) | 204 | (40.00) | 448 | (62.83) | 265 | (37.17) | 1.55 (1.20–2.00) | |
| No | 50 | (9.80) | 37 | (7.25) | 448 | (62.83 | 265 | (37.17) | 2.24 (1.47–3.57) | 0.16 |
Abbreviations: CI, confidence interval; OR, odds ratio.
aThe analysis was adjusted by age, smoking, drinking status and family history of cancer. Values in boldface indicate statistical significance.
bP value for heterogeneity.
Fig 1LncRNA-HOTAIR rs920778 SNP T variant allele exhibits enhanced enhancer activity and increases HOTAIR expression.
(A) Enhancer activity are presented as fold increase relative to negative control (NC, empty vector PGL3). “**” indicates P<0.01. Individuals with the risk allele T at rs920778 in both 38 normal cervical tissues (B) and 43 cervical cancer tissues (C) is significantly associated with increased HOTAIR expression than those with the CC genotypes. Expression levels of HOTAIR are detected by RT-PCR in cervical cancer tissues grouped to three genotypes (rs920778TT, rs920778CT or rs920778CC). “*” indicates P<0.05. (D) RT-PCR analysis of HOTAIR expression levels in cervical cancer cell lines (SiHa, Hela and Caski) compared with breast cancer cell MCF-7 and human embryo kidney epithelial cell 293T. (E) The HOTAIR expression level was analyzed by RT-PCR in 91 cervical cancer tissue samples. HOTAIR expression levels was significantly upregulated in cervical cancer tissues compared with their matched non-tumor cervical cancer tissues (P<0.05). T, tumor; N, no-tumor.
Fig 2High expression of lncRNA HOTAIR in cervical cancer tissues is associated with patients with tumor node metastasis (TNM) staging.
(A) HOTAIR expression was classified into two groups based on median value of HOTAIR expression in cervical cancer tissues. (B) The HOTAIR expression was significantly higher in patients with advanced pathological stage (II+III+IV) than those with lower pathological stage (0+I).